Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death‐1 monoclonal antibodies for advanced melanoma

Background Antiprogrammed death‐1 antibodies (anti‐PD1) have response rates of 40% in metastatic melanoma. Patients with poor performance status (PS) were excluded from clinical trials, yet use of anti‐PD1 is widespread in clinical practice. Literature regarding clinical and palliative care outcomes in patients with poor PS treated with anti‐PD1 is lacking. Methods Retrospective review of outcomes for all patients with advanced melanoma treated...